NHS-LIVERPOOL-CCG
12.1.2022 08:04:09 CET | Business Wire | Press release
Today, Liverpool Clinical Commissioning Group (CCG) and Community Pharmacy Liverpool kicked off a new clinical service that will allow more than 100 pharmacies to offer a 10-minute, point-of-care test to differentiate bacterial from viral respiratory infection.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220111006163/en/
The test, named FebriDx® , will be used for patients with an acute cough at pharmacies across Liverpool under a new minor ailments service known as Pharmacy First, to enable rapid diagnoses and appropriate antibiotic prescribing – without the need for a GP appointment first.
“It is often difficult for healthcare providers to determine if a respiratory infection is bacterial or viral without this type of rapid testing because the symptoms are nearly identical,” said Peter Johnstone, Head of Medicines Optimisation for Liverpool CCG.
“FebriDx lends itself to the Pharmacy First initiative really well – the test uses a small finger stick blood sample to differentiate a bacterial from viral acute respiratory infection in just 10 minutes, and we’re starting to offer this in local pharmacies to help ensure people get the right treatment.”
The FebriDx test has already been in use in some hospitals and GP Surgeries across the UK for three years, but this is the first time it has been used in the Merseyside region.
“Our goal is to provide patients with more convenient access to testing and treatment for acute cough under a new Patient Group Direction (PGD),” explains Matt Harvey, Chief Officer of Community Pharmacy Liverpool . “With the high volumes of patients with coughs and respiratory problems during the winter season, we see a real opportunity to bring this test into local pharmacies to help us provide treatment for patients more quickly – without the need for a GP appointment or prescription first.”
In addition to the convenience, clinical studies show that this test allows healthcare providers to rule out bacterial infections for their patients with 99% confidence, which can help reduce the unnecessary use of antibiotics and reduce antimicrobial resistance.
To learn more about this service, please visit: www.liverpoolccg.nhs.uk
About NHS Liverpool CCG
NHS Liverpool Clinical Commissioning Group (CCG) is responsible for commissioning (planning and buying) hospital and community health services for the people of Liverpool. It has a budget of around £840m a year. The CCG is made up of representatives from each of the city’s 85 GP practices, and is led by a Governing Body consisting of GPs from across the city. Visit the website at: www.liverpoolccg.nhs.uk
About Community Pharmacy Liverpool
Community Pharmacy Liverpool is Liverpool’s local pharmaceutical committee (LPC), an organisation which represents community pharmacies across the city. Visit the website at: www.liverpool-lpc.org.uk
View source version on businesswire.com: https://www.businesswire.com/news/home/20220111006163/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB to Host 2026 Digital Investor Day10.6.2026 14:30:00 CEST | Press release
SLB (NYSE: SLB) will host an Investor Day on Wednesday, June 17, 2026, in New York, where leadership will outline their vision for SLB’s Digital business as digital technologies and AI continue to reshape the energy industry. The presentation will highlight SLB’s integrated digital strategy and portfolio, scalable growth opportunities powered by AI, and financial profile and outlook. Olivier Le Peuch, chief executive officer, SLB, will present at 9:00 a.m. U.S. Eastern Time (ET), and will discuss SLB’s digital strategy and business outlook. Stephane Biguet, chief financial officer, SLB, will present at approximately 11:00 a.m. ET, and will discuss the financial profile of SLB’s Digital business, the market opportunity and SLB’s 2030 digital ambitions. Mr. Le Peuch and Mr. Biguet will be joined by divisional leadership, who will provide further insight into Digital’s competitive differentiation supported by its mission-critical platform, driving transformation for customers. A live webc
Wolters Kluwer expands its Libra AI workspace with authoritative Swiss legal content from leading publisher Stämpfli10.6.2026 14:00:00 CEST | Press release
Collaboration brings trusted Swiss legal expertise directly into AI‑supported legal research, drafting and review Wolters Kluwer Legal & Regulatory today announced the expansion of Libra by Wolters Kluwer, its AI-powered legal workspace, to include professional legal content from Stämpfli Publishers, one of Switzerland’s most respected legal publishers. As a result, Swiss legal professionals using Libra by Wolters Kluwer gain direct access to the legal literature that shapes their daily work – fully integrated into a single AI-supported workflow. The content offering includes commentaries, practitioner guides, yearbooks and selected journals from Stämpfli Publishers – including the renowned “Berner Kommentar”, and the company’s succinct commentaries and legal textbooks. In addition, primary sources of Swiss law at both federal and cantonal level are integrated into the workspace. The offering will be continuously expanded over time, with additional titles gradually integrated into the
Macrobond Launches AI Data Feed with MCP and Skill, Bringing Governed Macroeconomic Intelligence to Enterprise AI Workflows10.6.2026 14:00:00 CEST | Press release
Two new delivery components, MCP for conversational AI and Skill for programmatic access, enable institutions to retrieve trusted, licensed macroeconomic data directly within their AI environments. Macrobond today announced the general availability of the Macrobond AI Data Feed Service, a purpose-built product, enabling financial institutions to integrate governed macroeconomic intelligence directly into AI-powered research, investment, and strategy workflows. Available now with MCP, Skill and API delivery components, the AI Data Feed helps organizations accelerate macroeconomic research and insight generation and reduce reliance on fragmented or ungoverned data sources. By delivering reliable, licensed, economic data integrated directly within AI chat interfaces and coding environments, the AI Data Feed Service provides a trusted foundation for enterprise AI initiatives. As generative AI becomes embedded in research, investment, and strategy workflows, face a foundational challenge: m
Parse Biosciences Launches the Next Generation of its Immune Profiling Kits10.6.2026 14:00:00 CEST | Press release
Updated kits deliver improved sensitivity and receptor recovery for single cell immune repertoire profiling at unprecedented scale Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today launched the next generation of its Evercode™ TCR and Evercode™ BCR kits, shipping to customers worldwide. The updated kits deliver a streamlined workflow, better whole transcriptome sequencing library efficiency, and improved performance, enabling researchers to resolve rare clonotypes and profile immune responses at unprecedented scale. Immunology researchers are working to understand complex adaptive immune responses, but meaningful signals are often rare, transient, or difficult to capture across large, sample-limited studies. Parse's immune profiling portfolio combines scale, sensitivity, and fixation-first workflows with paired TCR or BCR and whole transcriptome profiling, helping researchers connect clonal identity to cell state across high-thro
GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region10.6.2026 13:47:00 CEST | Press release
The expanded partnership adds Denmark, Finland, Norway and Sweden to GENESIS Pharma’s existing network of thirteen Southeast European markets.It grants rights for the commercialization of Alnylam’s RNAi therapeutics for serious cardiomyopathy conditions and rare genetic diseases. GENESIS Pharma, a leading regional biopharma company focused on the commercialization of innovative medicines in Europe, today announced the expansion of its longstanding commercial partnership with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), the leading RNAi therapeutics company. The extended agreement broadens the geographical reach of the collaboration to include four Nordic markets -Denmark, Finland, Norway, and Sweden- alongside the thirteen markets in Southeast Europe already within the scope of the partnership. GENESIS Pharma shall commercialize a portfolio of RNAi therapeutics for serious cardiomyopathy conditions and rare genetic diseases across this expanded territory. The partnership, established
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
